Altogether, SGLT2 inhibitors seem to be an interesting therapeutic option for T2DM patients with NAFLD, but clinicians need to consider their efficacy and safety when individualizing the treatment [156]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.